

Alpha-GPC

DESCRIPTION

Alpha-GPC, provided by Douglas Laboratories[®], supplies 250 mg of glycerophosphocholine, a nutrient important for neurological health, in each vegetarian capsule.

FUNCTIONS

Glycerophosphocholine (also, known as alpha-GPC, and alpha-glycerophosphatidylcholine) is a water-soluble pro-phospholipid found in high quantities in adult tissue and breast milk. While not a true phospholipid, the body can convert it readily into phosphatidylcholine, the most abundant phospholipid found in the body. Glycerophosphocholine also plays important roles in the synthesis of acetylcholine and the attachment of phosphatidylcholine to DHA (docosahexaenoic acid, an essential fatty acid).

Human studies indicate that glycerophosphocholine may play important roles in maintaining neurological health.[†] In studies conducted on healthy, young adults, glycerophosphocholine offered significant protection against medication-induced memory loss and helped to enhance baseline mental performance. In middle-aged and elderly adults, glycerophosphocholine supports memory and proper cognitive function.[†] This compound has also shown superior benefit when compared to citicholine and oxiracetam. Glycerophosphocholine also has the ability to support growth hormone releasing hormone production, which in turn can promote proper growth hormone levels.

INDICATIONS

Alpha-GPC may be a useful dietary supplement for individuals wishing to support healthy cognitive and mental functioning.

FORMULA (#99255)

Each 2 Vegetarian Capsules contain

L-Alpha-glycerophosphocholine500 mg

SUGGESTED USE

Adults take 1-2 capsules daily or as directed by physician.

SIDE EFFECTS

No adverse side effects reported.

STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

REFERENCES

Canal N, Franceschi M, Alberoni M, Castiglioni C, De Moliner P, Longoni A. Effect of L-alpha-glycerol-phosphorylcholine on amnesia caused by scopolamine. *Int J Clin Pharmacol Ther Toxicol.* 1991 Mar;29(3):103-7.

De Jesus Moreno Moreno M Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. *Clin Ther.* 2003 Jan;25(1):178-93

Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M. A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerol-phosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. *J Int Med Res.* 1991 Jul-Aug;19(4):330-41.

Frattola L, et al. Multicenter clinical comparison of the effects of choline alfoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. *Curr Ther Res* 1991;49(4):683-693.

Mandat T, Wilk A, Manowicz R, Koziarski A, Zielinski G, Podgorski JK.. [Preliminary evaluation of risk and effectiveness of early choline alfoscerate treatment in craniocerebral injury]. *Neurol Neurochir Pol.* 2003 Nov-Dec;37(6):1231-8.

[†]These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

Distributed by
Douglas Laboratories
552 Newbold St., London, Ontario N6E 2S5
Phone: 866.856.9954 Fax: 888.220.9441
Email: info@douglaslabs.ca Website: www.douglaslabs.ca